Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response kinetics of CAIV-T (FluMist) in healthy adults
NCT00192309Phase 2Completed
- Sponsor
- MedImmune
- Start
- Sep 2001
- Primary completion
- Dec 2001
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of live attenuated influenza vaccine in influenza, sponsored by MedImmune. Primary endpoint: Hemagglutination inhibition antibody response. Started Sep 2001; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00192309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192309.